Country: Australia
Language: English
Source: Department of Health (Therapeutic Goods Administration)
Aflibercept
Sanofi-Aventis Australia Pty Ltd
Aflibercept
LIDAVEG ® 1 LIDAVEG ® _(LID-AR-VEG) _ _Aflibercept (rch) (a-flib-er-cept) _ CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET This leaflet answers some common questions about Lidaveg. It does not contain all the available information. It does not take the place of talking to your doctor. All medicines have risks and benefits. Your doctor has weighed the risks of you taking Lidaveg against the benefits they expect it will have for you. IF YOU HAVE ANY CONCERNS ABOUT TAKING THIS MEDICINE, ASK YOUR DOCTOR. Keep this leaflet as you may need to read it again. WHAT LIDAVEG IS USED FOR Lidaveg is used to treat advanced large bowel cancer (that is, cancer in the colon or rectum) in combination with chemotherapy agents. ASK YOUR DOCTOR IF YOU HAVE ANY QUESTIONS ABOUT WHY THIS MEDICINE HAS BEEN PRESCRIBED FOR YOU. Lidaveg contains the active ingredient aflibercept. Lidaveg is an anti-cancer medicine that blocks the growth of blood vessels that provide nutrients and oxygen to cancer cells. This prevents the growth of the cancer cells. Your doctor may have prescribed Lidaveg for another purpose. This medicine is only available with a doctor's prescription. Lidaveg is not addictive. BEFORE YOU ARE GIVEN LIDAVEG DO NOT RECEIVE LIDAVEG IF YOU ARE ALLERGIC TO LIDAVEG OR ANY OF THE INGREDIENTS LISTED AT THE END OF THIS LEAFLET. Some symptoms of an allergic reaction include: skin rash, hives, itching or redness of the skin; shortness of breath, wheezing or difficulty breathing; or swelling of the face, lips, tongue or other parts of the body. LIDAVEG SHOULD NOT BE USED IN YOUR EYE, SINCE IT MAY SEVERELY DAMAGE IT. DO NOT RECEIVE LIDAVEG: AFTER THE EXPIRY DATE (EXP) PRINTED ON THE VIAL. IF THE PACKAGING IS DAMAGED OR SHOWS SIGNS OF TAMPERING. TELL YOUR DOCTOR IF YOU ARE PREGNANT OR ARE PLANNING ON HAVING A BABY. Do not use Lidaveg if you are pregnant unless otherwise advised by your doctor. Lidaveg may harm your unborn baby. Your doctor will advise you about using effective contraception during treatment with Lidaveg Read the complete document
PRODUCT INFORMATION Lidaveg 100mg/4mL and 200mg/8mL Injection, Concentrated lidaveg-ccdsv4-piv4-9may16 Page 1 of 29 PRODUCT INFORMATION LIDAVEG ® NAME OF MEDICINE AUSTRALIAN APPROVED NAME Aflibercept (rch) CHEMICAL STRUCTURE Aflibercept is a recombinant protein consisting of sequences derived from human vascular endothelial growth factor (VEGF) receptor extracellular domains fused to the Fc portion of human immunoglobulin G1 (IgG1). The extracellular domain sequences come from two different VEGF receptors, VEGFR1 (also known as Flt-1) and VEGFR2 (also known as KDR or Flk-1). Each of the VEGF receptors are composed of seven immunoglobulin (Ig) domains in their extracellular regions, with Ig domains 2 and 3 contributing the majority of the binding energy for VEGF. Thus the amino acid sequence structure of aflibercept comprises Ig domain 2 from VEGFR1, fused to Ig domain 3 from VEGFR2, which is in turn fused to the Fc domain of IgG1. There are no extraneous linker sequences between any of the peptide domains. The presumptive Ig domain structure of aflibercept is provided in Figure 1. FIGURE 1 - STRUCTURE OF AFLIBERCEPT AFLIBERCEPT 2 2 3 3 I g G 1 1 2 3 4 5 6 7 1 2 3 4 5 6 7 V E G F R 1 V E G F R VEGF Trap PRODUCT INFORMATION Lidaveg 100mg/4mL and 200mg/8mL Injection, Concentrated lidaveg-ccdsv4-piv4-9may16 Page 2 of 29 MOLECULAR FORMULA Aflibercept molecular formula (without glycosylation) is C 4318 H 6788 N 1164 O 1304 S 32 . MOLECULAR WEIGHT 115 kDa CHEMICAL NAME 1. Vascular endothelial growth factor receptor type VEGFR-1 (synthetic human immunoglobulin domain 2 fragment) fusion protein with vascular endothelial growth factor receptor type VEGFR- 2 (synthetic human immunoglobulin domain 3 fragment) fusion protein with immunoglobulin G1 (synthetic Fc fragment), dimer. 2. des-432-lysine-[human vascular endothelial growth factor receptor 1-(103-204)-peptide (containing Ig-like C2-type 2 domain) fusion protein with human vascular endothelial growth factor receptor 2- (206-308)-peptide (containing Ig-like C2-type 3 do Read the complete document